Shares of GC Green Cross Wellbeing closed at 14,680 won on July 25, marking a 19.16% increase from the prior day. The surge followed the company's announcement of the domestic launch of Giselle Rebonne, a human tissue-based extracellular matrix (ECM) skin booster. This development signals growing investor confidence in advanced aesthetic medicine products amid expanding demand for regenerative skin treatments.
Breakthrough in Skin Booster Technology
Giselle Rebonne relies on human acellular dermal matrix (hADM), derived from human tissue and processed to remove cells and immune-triggering factors. Unlike traditional skin boosters that indirectly stimulate collagen production, this product supplies the ECM structure directly, supporting tissue remodeling at a structural level. MS Bio, a specialist in human tissue and biomaterials, applies its proprietary decellularization process to ensure biocompatibility, which reduces risks of immune rejection and inflammation.
Strategic Expansion of Aesthetic Portfolio
GC Green Cross Wellbeing oversees raw material control and supply via its tissue bank at the Eumseong plant in North Chungcheong Province. The launch completes a portfolio that now includes placenta injection Laennec, dermal fillers, skin boosters, and botulinum toxin Innovo. This move mirrors industry trends, such as Hugel's co-promotion with Hans Biomed on the ECM skin booster Cellrderm, and CG Bio's planned package sales with Daewoong Pharmaceutical's Nabota and V-Olet.
Implications for the Regenerative Aesthetics Market
The product's focus on direct ECM delivery positions it as a next-generation option for skin regeneration, addressing limitations of earlier boosters. As aesthetic medicine shifts toward tissue-based solutions, companies like GC Green Cross Wellbeing strengthen their foothold in a competitive landscape. Investor reactions underscore potential for sustained growth, though success will depend on regulatory approvals, clinical outcomes, and market adoption of these advanced biomaterials.
